The Effect of Peroxisome Prouferators on Microsomal. Peroxisomal, and Mitochondrial Enzyme Activities in the Liver and Kidney

References

• Reddy J. K., Krishnakantha T. P., Azarnoff D. L., Moody D. E. 1-Methyl-4-piperidyl-te-bis-chlorophenoxy) acetate. A new hypolipidemic peroxisome proliferator. Res. Commun. Chem. Pathol. Pharmacol 1975; 10: 589–592
   PubMedGoogle Scholar
• Ishii H., Fukumori N., Horie S., Suga T. “Effects of fat content in the diet on hepatic peroxisomes of the rat”. Biochim. Biophys. Acta 1980; 617: 1–11
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Lalwani N. D., Dabholkar A. S., Reddy M. K., Qureshi S. A. “Increased peroxisomal activity in the liver of vitamin E deficient rats”. Biochem. Int. 1981; 3: 41–49
   Google Scholar
• Vainio H., Linnainmaa K., Kähönen M., Nickels J., Hietanen E., Marniemi J., Peltonen P. “Hypolipidemia and peroxisome proliferation induced by phenoxyacetic acid herbicides in rats”. Biochem. Pharmacol 1983; 32: 2775–2779
   PubMed Web of Science ®Google Scholar
• Kawashima Y., Katoh H., Nakajima S., Kozuka H., Uchiyama M. Effects of 2,4-dichlorophenoxyacetic acid and 2,4,5-tricholorphenoxyacetic acid on peroxisomal enzymes in rat liver. Biochem. Pharmacol 1984; 33: 241–245
   PubMed Web of Science ®Google Scholar
• Lewis B. The Hyperlipidaemias: Clinical and Laboratory Practice. Blackwell Scientific Publications. 1976, chaps. 9, 10, and 15
   Google Scholar
• Lewis B. Oxford Textbook of Medicine, D. J. Weatherall, J. G. G. Ledingham, D. A. Warrell. Oxford University Press. 1983; vol. 1, sec. 9.
   Google Scholar
• Rogers H. J., Spector R. G., Trounce J. R. A Textbook of Clinical Pharmacology. Hodder and Stoughton. 1981, chap. 16.
   Google Scholar
• Rogers H., Spector R. Aids to Pharmacology. Churchill Livingstone, London 1983; 186–187
   Google Scholar
• British National Formulary. BMA and Pharmaceutical Society of Great Britain. 1985, no. 10, chap. 2.
   Google Scholar
• Gillman A., Goodman L., Rail T., Murad F. The Pharmacological Basis of Therapeutics, 7th ed. Macmillan. 1983, chap. 34.
   Google Scholar
• Bowman W. C., Rand M. J. Textbook of Pharmacology, 2nd ed. Blackwell Scientific Publishing. 1980, chap. 28.
   Google Scholar
• The Coronary Drug Project Research Group. “Clofibrate and niacin in coronary heart disease”. J. Am. Med. Assoc 1975; 231: 360–381
   PubMed Web of Science ®Google Scholar
• Oliver M. Cholesterol, coronaries, clofibrate and death. N. Engl. J. Med. 1978; 299: 1360–1362
   PubMed Web of Science ®Google Scholar
• Hess R., Staubli W., Riess W. Nature of the hepatomegalic effect produced by ethyl-chlorophenoxyisobutyrate in the rat. Nature 1965; 208: 856–858
   PubMed Web of Science ®Google Scholar
• Fahimi D. H., Reinicke A., Sujatta M., Yokota S., C-Zel M. “The short and long term effects of bezafibrate in the rat”. Ann. NY Acad. Sci. 1982; 383: 111–135
   Google Scholar
• Lalwani N. D., Reddy M. K., Qureshi S. A., Moehle C. M., Hayashi H., Reddy J. K. Noninhibitory effect of antioxidants ethoxyquin, 2(3)-tert-butyl-4-hydroxyanisole and 3,5-di-tert-butyl-4-hydroxytoluene on hepatic peroxisome proliferation and peroxisomal fatty acid β-oxidation induced by a hypolipidaemic agent in rats. Cancer Res 1983; 43: 1680–1687
   PubMed Web of Science ®Google Scholar
• Orton T. C., Adam H. K., Bentley M., Holloway B., Tucker M. J. “Clobuzarit: Species differences in the morphological and biochemical response of the liver following chronic administration”. Toxicol. Appl. Pharmacol 1984; 73: 138–151
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Lalwani N. D. “Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidaemic drugs and industrial plasticisers to man”. CRC Crit. Rev. Toxicol 1983; 12: 1–58
   Web of Science ®Google Scholar
• Reddy J. K. Induction by hypolipidaemic drugs procetofen, tiadenol and gemfibrozil of peroxisome proliferation in the rat liver, abstract 284. Fed. Proc 1980; 39: 98
   Google Scholar
• Moody D. E., Reddy J. K. Increase in hepatic carnitine acetyltransferase activity associated with peroxisomal (microbody) proliferation induced by the hypolipidaemic drugs clofibrate, nafenopin and methyl clofenapate. Res. Commun. Chem. Pathol. Pharmacol 1974; 9: 501–510
   PubMedGoogle Scholar
• Reddy J., Svoboda D., Azarnoff D. Microbody proliferation in liver induced by nafenopin, a new hypolipidaemic drug: Comparison with CPIB. Biochem. Biophys. Res. Commun 1973; 52: 537–543
   PubMed Web of Science ®Google Scholar
• Moody D. E., Reddy J. K. “Morphometric analysis of the ultrastructural changes in rat liver induced by the peroxisome proliferates SaH-42–348”. J. Cell. Biol 1976; 71: 768–780
   PubMed Web of Science ®Google Scholar
• Hruban Z., Swift H., Slesers A. “Ultrastructural alterations of hepatic microbodies”. Lab. Invest 1966; 15: 1884–1901
   PubMed Web of Science ®Google Scholar
• Bakke O. M., Berge R. K. “Induction of peroxisomal enzymes and palmitoyl-CoA hydrolase in rats treated with cholestyramine and nicotinic acid”. Biochem, Pharmacol 1984; 33: 3077–3080
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Krishnakantha T. P. Hepatic peroxisome proliferation: Induction by two novel compounds structurally unrelated to clofibrate. Science 1975; 190: 787–789
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Moody D. E., Azarnoff D. L., Rao M. S. “Di-(2-ethyIhexyl) phthalate: An industrial plasticiser induces hypolipidaemia and enhances hepatic catalase and carnitine acetyltransferase activities in rats and mice”. Life Sci 1976; 18: 941–946
   PubMed Web of Science ®Google Scholar
• Moody D. E., Reddy J. K. “Hepatic peroxisome (microbody) proliferation in rats fed plasticisers and related compounds”. Toxicol. Appl. Pharmacol 1978; 45: 497–504
   PubMed Web of Science ®Google Scholar
• Lake B. G., Gangolli S. D., Grasso P., Lloyd A. G. “Studies on the hepatic effects of orally administered di-(2-ethylhexyl) phthalate in the rat”. Toxicol. Appl. Pharmacol 1975; 32: 355–367
   PubMed Web of Science ®Google Scholar
• Thomas J. A., Thomas M. J. Biological effects of di-(2-ethylhexyl) phthalate and other phthalic acid esters. CRC Crit. Rev. Toxicol 1984; 13: 283–317
   Web of Science ®Google Scholar
• Reddy J. K., Azarnoff D. L., Hignite C. E. “Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens”. Nature 1980; 283: 397–398
   PubMed Web of Science ®Google Scholar
• Mann A. H., Price S. C., Mitchell F. E., Grasso P., Hin-Ton R. H., Bridges J. W. Comparison of the short-term effects of di(2-ethylhexyl)phthalate, di(n-hexyl)phthalate and di(rt-octy) phthalate in rats. Toxicol. Appl. Pharmacol 1985; 77: 116–132
   PubMed Web of Science ®Google Scholar
• Azarnoff D. L., Tucker D. R., Barr G. A. “Studies with ethylchlorophenoxyisobutyrate (clofibrate)”. Metabolism 1965; 14: 959–965
   PubMedGoogle Scholar
• Piatt D. S., Cockrill B. L. Biochemical changes in rat liver in response to treatment with drugs and other agents. I. Effects of anticonvulsant, anti-inflammatory, hypocholesterolaemic and adrenergic β-blocking-agents. Biochem. Pharmacol 1969; 18: 429–444
   PubMed Web of Science ®Google Scholar
• Beckett R. B., Weiss R., Stitzel R. E., Cenedella R. J. “Studies on the hepatomegaly caused by the hypolipidaemic drugs nafenopin and clofibrate”. Toxicol. Appl. Pharmacol 1972; 23: 42–53
   PubMed Web of Science ®Google Scholar
• Dalton C., Hope W. C., Hope H. R., Sheppard H. “Relationship of serum triglyceride lowering to changes in hepatic composition induced by different classes of drugs”. Biochem. Pharmacol 1974; 23: 685–696
   PubMed Web of Science ®Google Scholar
• Leighton F., Coloma L., Koenig C. Structure, compositon, physical properties and turnover of proliferated peroxisomes: A study of the trophic effects of Su-13437 on rat liver. J. Cell Biol 1975; 67: 281–309
   PubMed Web of Science ®Google Scholar
• Hartman H. A., Bagdon R. E., Van Ryzin R. J., Tousimis A. J. Comparative studies of the hepatic effects of the hypolipidaemic agents SaH-42,348 (l-methyl-4-piperdyl)to(p-chlorophenoxy) acetate) and clofibrate (ethylchlorophenoxy-isobutyrate) in rats. Toxicol. Appl. Pharmacol 1970; 17: 315–316
   Web of Science ®Google Scholar
• Salvador R. A., Haber S., Atkins C., Gommi B. W., Welch R. M. Effect of clofibrate and l-methyl-4-piperidyl-bis(p-chloro-phenoxy)acetate (Sandoz 43–348) on steroid and drug metabolism by rat liver microsomes. Life Sci 1970; 9: 397–407
   PubMed Web of Science ®Google Scholar
• Levine W. G., Ord M. G., Stocken L. A. “Some biochemical changes associated with nafenopin-induced liver growth in the rat”. Biochem. Pharmacol 1977; 26: 939–942
   PubMed Web of Science ®Google Scholar
• Cohen A. J., Grasso P. “Review of the hepatic response to hypolipidaemic drugs in rodents and assessment of its toxicological significance to man”. Food Cosmet. Toxicol 1981; 19: 585–605
   PubMedGoogle Scholar
• Reddy J. K., Rao M. S., Azarnoff D. L., Sell S. Mitogenic and carcinogenic effects of a hypolipidaemic peroxisome proliferator (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid (Wy-14,643) in rat and mouse liver. Cancer Res 1979; 39: 152–161
   PubMed Web of Science ®Google Scholar
• Facino R. M., Carini M. Effect of the hypolipidaemic drug bezafibrate on the hepatic MFO system of the rat: Heterogeneity in mono-oxygenase responses. Pharmacol. Res. Commun 1981; 13: 861–871
   PubMedGoogle Scholar
• Orton T. C., Parker G. L. The effect of hypolipidaemic drugs on the hepatic microsomal drug metabolising enzyme system of the rat: Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid. Drug Metab. Dispos 1982; 10: 110–115
   PubMed Web of Science ®Google Scholar
• Ganning A. E., Dallner G. “Induction of peroxisomes and mitochondria by di-(2-ethylhexyl)phthalate”. Febs Lett 1981; 130: 77–79
   PubMed Web of Science ®Google Scholar
• Lake B. G., Pels Rijcken W. R., Gray T. J. B., Foster J. R., Gangolli S. D. Comparative studies of the hepatic effects of di and mono-rt octyl phthalates, di-(2-ethylhexyl)phthalate and clofibrate in the rat. Acta Pharmacol. Toxicol 1984; 54: 167–176
   PubMedGoogle Scholar
• Bieri F., Bentley P., Waechter F., Staubli W. Use of primary cultures of adult rat hepatocytes to investigate mechanisms of action of nafenopin, a hepatocarcinogenic peroxisome proliferator. Carcinogensis 1984; 5: 1033–1039
   PubMed Web of Science ®Google Scholar
• Armato U., Romano F., Andreis P. The tumour promoters TPA, PB and nafenopin and the prostaglandins of the A, E and F series overcome the Gl/S block imposed by extacellular calcium deprivation on neonatal rat hepatocytes. PG. Leuko. Med. 1984; 13: 237–247
   PubMedGoogle Scholar
• Lazarow P. B., Shio H., Leyroy-Houyet M. A. “Specificity in the action of hypolipidaemic drugs: Increase of peroxisomal β-oxidation largely dissociated from hepatomegaly and peroxisome proliferation in the rat”. J. Lipid Res. 1982; 23: 317–326
   PubMed Web of Science ®Google Scholar
• Cytochrome P-450, R. Sato, T. Omura. Academic Press. 1978; 1–233
   Google Scholar
• Lu A. Y. H., West S. B. “Multiplicity of mammalian microsomal cytochromes P-450”. Pharmacol. Rev. 1980; 31: 277–295
   Web of Science ®Google Scholar
• Makowski R., Davies R., Gibson G. G. Species differences in cytochromes P-450 and their corresponding messenger RNA's. Rev. Drug. Metab. Drug Inter 1982; 4: 123–170
   PubMedGoogle Scholar
• Svoboda D. J., Azarnoff D. L. Response of hepatic microbodies to a hypolipidaemic agent, ethylchlorophenoxy-isobutyrate (CPIB). J. Cell Biol 1966; 30: 442–450
   PubMedGoogle Scholar
• Platt D. S., Thorp J. M. Changes in the weight and composition of the liver in the rat, dog and monkey treated with ethyl chlorophenoxyisobutyrate. Biochem. Pharmacol 1966; 15: 915–925
   PubMed Web of Science ®Google Scholar
• Landriscina C., Gnoni G. V., Quagliariello E. “On the mode of action of clofibrate on lipid metabolism: Inhibition of rat liver microsomal fatty acid synthesis”. Biochem. Med. 1975; 12: 356–364
   PubMedGoogle Scholar
• Anthony L. E., Schmucker D. L., Mooney J. S., Jones A. L. “A quantitative analysis of fine structure and drug metabolism in livers of clofibrate-treated young adult and retired breeder rats”. J. Lipid Res. 1978; 19: 154–165
   PubMed Web of Science ®Google Scholar
• Orton T. C., Higgins J. E. The effect of hypolipidaemic agents on liver drug metabolising enzyme system. Toxcicol. Appl. Pharmacol 1979; 48(A126)251
   Google Scholar
• Odum J., Orton T. C. Rat hepatic microsomal cytochrome(s) P-450 induced by clofibrate. Br. J. Pharmacol 1980; 69: 317, abstract
   Google Scholar
• Burke C. L., Hajra A. K. “Clofibrate feeding increases the activities of rat liver dihydroxyacetone phosphate acyltransferase and glycerol-3-phosphate acyltransferase”. Biochem. Int. 1980; 1: 312–318
   Google Scholar
• Pollard A. D., Brindley D. M. Effect of chronic clofibrate feeding on the activities of enzymes involved in glycerolipid synthesis and in peroxisomal metabolism in rat liver. Biochem. Pharmacol 1982; 31: 1650–1652
   PubMed Web of Science ®Google Scholar
• Wakabayashi K., Shimazono N. Studies on ω-oxidation of fatty acids in vitro. I. Overall reaction and intermediate. Biochim. Biophys. Acta 1963; 70: 132–142
   PubMed Web of Science ®Google Scholar
• Lu A. Y. H., Coon M. J. “Role of hemoprotein P-450 in fatty acid omega-hydroxylation in a soluble enzyme system from liver microsomes”. J. Biol. Chem 1968; 243: 1331–1332
   PubMed Web of Science ®Google Scholar
• Ichihara K., Kusunose E., Kusunose M. “Some properties and distribution of the omega-hydroxylation system of medium chain fatty acids”. Biochem. Biophys. Acta 1969; 176: 704–712
   PubMed Web of Science ®Google Scholar
• Björkhem I., Danielsson H. “Omega- and (omega-l)-oxidation of fatty acids by rat liver microsomes”. Eur. J. Biochem 1970; 17: 450–459
   PubMedGoogle Scholar
• Okita R. T., Masters B. S. S. “Effect of phenobarbital treatment and cytochrome P-450 inhibitors on the laurate omega- and (omega-1) hydroxylase activities of rat liver microsomes”. Drug Metab. Dispos 1980; 8: 147–151
   PubMed Web of Science ®Google Scholar
• Gibson G. G., Orton T. C., Tamburini P. P. “Cytochrome P-450 induction by clofibrate”. Biochem J 1982; 203: 161–168
   PubMed Web of Science ®Google Scholar
• Parker G. L., Orton T. C. Induction by oxyisobutyrates of hepatic and kidney microsomal cytochrome P-450 with specificity towards hydroxylation of fatty acids. Biochemistry, Biophysics, and Regulation of Cytochrome P-450. Elsevier Press. 1980; 373–377
   Google Scholar
• Fournel S., Magdalou J., Batt A. M., Siest G. “Comparative study of four hypolipidaemic agents on the activity of drug metabolising enzymes in rat liver microsomes”. Int. J. Clin. Pharm. Res. 1984; 111: 431–436
   Google Scholar
• Hammock B. D., Ota K. “Differential induction of cytosolic epoxide hydrolase and glutathione S-transferase activities”. Toxicol. Appl. Pharmacol 1983; 71: 254–265
   PubMed Web of Science ®Google Scholar
• Lake B. G., Gray T. J. B., Stubberfield C. R., Beamand J. A., Gangolli S. D. “Induction of lauric acid hydroxylation and maintenance of cytochrome P-450 content by clofibrate in primary cultures of rat hepatocytes”. Life Sci 1983; 33: 249–254
   PubMed Web of Science ®Google Scholar
• Lake B. G., Gray T. J. B., Pels Rijcken W. R., Beamand J. A., Gangolli S. D. “The effect of hypolipidaemic agents on peroxisomal β-oxidation and MFO activities in primary cultures of rat hepatocytes: Relationship between induction of palmitoyl-CoA oxidation and lauric acid hydroxylation”. Xenobiotics 1984; 14: 269–276
   PubMed Web of Science ®Google Scholar
• Kramar R., Kremser K. “Enhancement of aldehyde dehydrogenase activity in rat liver by clofibrate feeding”. Enzyme 1984; 31: 17–20
   PubMedGoogle Scholar
• Waechter F., Bieri F., Staubli W., Bentiey P. “Induction of cytosolic and microsomal epoxide hydrolases by the hypolipidaemic compound nafenopin in the mouse liver”. Biochem. Pharmacol 1984; 33: 31–34
   PubMed Web of Science ®Google Scholar
• Tamburini P. P., Masson H. A., Bains S. K., Makowski R. J., Morris B., Gibson G. G. Multiple forms of hepatic cytochrome P-450: Purification, characterisation and comparison of a novel clofibrate-induced isoenzyme with other major forms of cytochrome P-450. Eur. Biochem 1984; 139: 235–246
   PubMedGoogle Scholar
• Mangham B. A., Foster J. R., Lake B. G. “Comparison of the hepatic and testicular effects of orally administered di-(2-ethyl-hexyl)phthalate and dialkyl 79 phthalate in the rat”. Toxicol. Appl. Pharmacol 1981; 61: 205–214
   PubMed Web of Science ®Google Scholar
• Agarwal D. K., Agarwal S., Seth P. K. Effect of di-(2-ethylhexyl)phthalate on drug metabolism, lipid peroxidation and sulfhydral content of rat liver. Drug Metab. Dispos 1982; 10: 77–80
   PubMed Web of Science ®Google Scholar
• Walseth F., Toftgard R., Nilsen O. G. Phthalate esters. I: Effects on cytochrome P-450 mediated metabolism in rat liver and lung, serum enzymatic activities and serum protein levels. Arch. Toxicol 1982; 50: 1–10
   PubMed Web of Science ®Google Scholar
• Walseth F., Nilsen O. G. “Phthalate esters. II: Effects of inhaled dibutyl phthalate on cytochrome P-450 mediated metabolism in rat liver and lung”. Arch. Toxicol 1984; 55: 132–136
   PubMed Web of Science ®Google Scholar
• Lake B. G., Tredger J. M., Gray T. J. B., Stubberfield C. R., Hodder K. D., Gangolli S. D., Williams R. “The effect of peroxisome proliferators on the metabolism and spectral interaction of endogenous substrates of cytochrome P-450 in rat hepatic microsomes”. Life Sci 1984; 35: 2621–2626
   PubMed Web of Science ®Google Scholar
• Israelsson U., Hamberg M., Samuelsson B. Biosynthesis of 19-hydroxy-prostaglandin A. Eur. J. Biochem 1969; 11: 390–394
   PubMedGoogle Scholar
• Kupfer D., Navarro J. “Metabolism of prostaglandin Ai by hepatic microsomal mono-oxygenase P-450 system in the guinea pig and rat”. Life Sci 1976; 18: 507–514
   PubMed Web of Science ®Google Scholar
• Kupfer D., Navarro J., Piccolo D. E. Hydroxylation of prostaglandins A1 and E1 by liver microsomal mono-oxygenase: Characteristics of the enzyme system in the guinea pig. J. Biol. Chem 1978; 253: 2804–2811
   PubMed Web of Science ®Google Scholar
• Theoharides A. D., Kupfer D. Evidence for different hepatic microsomal mono-oxygenases catalysing omega- and (omega-1) hydroxylations of prostglandins E1 and E2: Effects of inducers of mono-oxygenase on kinetic constants of prostaglandin hydroxylation. J. Biol. Chem 1981; 256: 2168–2175
   PubMed Web of Science ®Google Scholar
• Capdevila J., Chacos N., Werringloer J., Prough R. A., Estabrook R. W. “Liver microsomal cytochrome P-450 and oxidative metabolism of arachidonic acid”. Proc. Natl. Acad. Sci. 1981; 78: 5362–5366
   PubMed Web of Science ®Google Scholar
• Oliw E. H., Oates J. A. Oxygenation of arachidonic acid by hepatic microsomes of the rabbit: Mechanism of biosynthesis of 2 vicinal dihydroxyeicosatrienoic acids. Biochem. Biophys. Acta 1981; 666: 327–340
   PubMed Web of Science ®Google Scholar
• Chacos N., Falck J. R., Wixtrom C., Capdevila J. “Novel epoxides formed during the liver cytochrome P-450 oxidation of arachidonic acid”. Biochem. Biophys. Res. Commun 1982; 104: 916–922
   PubMed Web of Science ®Google Scholar
• Capdevila J., Marnett L. J., Chacos N., Prough R. A., Eastbrook R. W. “Cytochrome P-450 dependant oxygenation of arachidonic acid to hydroxyicosatetraenoic acids”. Proc. Natl. Acad. Sci. 1982; 79: 767–770
   PubMed Web of Science ®Google Scholar
• Oliw E. H., Guengerich F. P., Oates J. A. “Oxygenation of arachidonic acid by hepatic mono-oxygenases: Isolation and metabolism of 4 epoxide intermediates”. J. Biol. Chem 1982; 257: 3771–3781
   PubMed Web of Science ®Google Scholar
• Chacos N., Capdevila J., Falck J. R., Manna S., Martin C., Gill-Wixtrom S. S., Hammock B. D., Estabrook R. W. The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. Arch. Biochem. Biophys 1983; 223: 639–648
   PubMed Web of Science ®Google Scholar
• Capdevila J., Kim Y. R., Martin-Wixtrom C., Falck J. R., Manna S., Estabrook R. W. “Influence of a fibric acid-type of hypolipidemic agent on the oxidative metabolism of arachidonic acid by liver microsomal cytochrome P-450”. Arch. Biochem. Biophys 1985; 243: 8–19
   PubMed Web of Science ®Google Scholar
• Bains S. K., Gardiner S. M., Mannweiler K., Gillett D., Gibson G. G. “Immunochemical study on the contribution of hypo-lipidaemic-induced cytochrome P-452 to the metabolism of lauric acid and arachidonic acid”. Biochem. Pharmacol 1985; 34: 3221–3229
   PubMed Web of Science ®Google Scholar
• De Duve C. The peroxisome: A new cytoplasmic organelle. Proc. Roy. Soc. B. 1969; 173: 71–83
   Web of Science ®Google Scholar
• Novikoff A. B., Goldfischer S. Visualization of peroxisomes (microbodies) and mitochondria with diaminobenzidine. J. Histochem. Cytochem 1969; 17: 675–680
   PubMed Web of Science ®Google Scholar
• De Duve C. “Evolution of the peroxisome”. Ann. NY Acad. Sci. 1970; 168: 369–381
   Web of Science ®Google Scholar
• Afzelius B. “The occurrence and structure of microbodies: A comparative study”. J. Cell Biol 1965; 26: 835–843
   PubMed Web of Science ®Google Scholar
• Hruban Z., Swift H. Uricase: Localization in hepatic microbodies. Science 1964; 146: 1316–1317
   PubMed Web of Science ®Google Scholar
• Antonenkov V. D., Panchenko L. F. Organization of urate oxidase in peroxisomal nucleoids. FebsLett 1978; 88: 151–154
   PubMed Web of Science ®Google Scholar
• De Duve C., Baudhuin P. “Peroxisomes (microbodies and related particles)”. Physiol. Rev. 1966; 46: 323–357
   PubMed Web of Science ®Google Scholar
• Masters C., Crane D. “The role of peroxisomes in lipid metabolism”. TIBS 1984; 9: 314–317
   Web of Science ®Google Scholar
• Lazarow P. B., De Duve C. A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidaemic drug. Proc. Natl. Acad. Sci. 1976; 73: 2043–2046
   PubMed Web of Science ®Google Scholar
• Lazarow P. B. Rat liver peroxisomes catalyse the β-oxidation of fatty acids. J. Biol. Chem 1978; 253: 1522–1528
   PubMed Web of Science ®Google Scholar
• Beard M. E., Novikoff A. B. “Distribution of peroxisomes (microbodies) in the nephron of the rat”. J. Cell. Biol 1969; 42: 501–518
   PubMed Web of Science ®Google Scholar
• Allen J. M., Beard M. “α-Hydroxyacid oxidase: Localisation in renal microbodies”. Science 1965; 149: 1507–1509
   PubMed Web of Science ®Google Scholar
• Inestrosa N. C., Bronfman M., Leighton F. “Detection of peroxisomal fatty acyl-coenzyme A oxidase activity”. Biochem. J. 1979; 182: 779–788
   PubMed Web of Science ®Google Scholar
• Tolbert N. E. “Metabolic pathways in peroxisomes and glyoxysomes”. Ann. Rev. Biochem 1981; 50: 133–157
   PubMed Web of Science ®Google Scholar
• Yokota S., Fahimi H. D. “Immunoelectron microscopic localization of acyl CoA oxidase in rat liver and kidney”. Ann. NY Acad. Sci. 1982; 386: 491–494
   Web of Science ®Google Scholar
• Markwell M. A. K., McGroarty E. J., Bieber L. L., Tolbert N. E. “The subcellular distribution of carnitine acyltransferases in mammalian liver and kidney”. J. Biol. Chem 1973; 248: 3426–3432
   PubMed Web of Science ®Google Scholar
• Markwell M. A. K., Bieber L. L., Tolbert N. E. Differential increase of hepatic peroxisomal, mitochondrial and microsomal carnitine acyltransferases in clofibrate fed rats. Biochem. Pharmacol 1977; 26: 1697–1702
   PubMed Web of Science ®Google Scholar
• Hajra A. K., Burke C. L., Jones C. L. “Subcellular localization of acyl coenzyme A: Dihydroxyacetone phosphate acyltransferases in rat liver peroxisomes (microbodies)”. J. Biol. Chem 1979; 254: 10896–10900
   PubMed Web of Science ®Google Scholar
• Osumi T., Hashimoto T. “Peroxisomal β-oxidation system of rat liver: Copurification of enoyl-CoA-hydratase and 3-hydroxyacyl-CoA dehydrogenase”. Biochem. Biophys. Res. Commun 1979; 89: 580–584
   PubMed Web of Science ®Google Scholar
• Osumi T., Hashimoto T. “Purification and properties of mitochondrial and peroxisomal 3-hydroxyacyl CoA dehydrogenase from rat liver”. Arch. Biochem. Biophys 1980; 203: 372–383
   PubMed Web of Science ®Google Scholar
• Lalwani N. D., Reddy M. K., Mangkornkanok-Mark M., Reddy J. K. Induction, immunochemical identity and immunofluorescence localization of an 80,000 molecular-weight peroxisome-proliferation associated polypeptide (polypeptide PPA-80) and peroxisomal enoyl CoA hydratase of mouse liver and renal cortex. Biochem J 1981; 198: 177–186
   PubMed Web of Science ®Google Scholar
• Miyazawa S., Furuta S., Hashimoto T. “Induction of novel long chain acyl CoA hydrolase in rat liver by administration of peroxisome proliferators”. Eur. J. Biochem 1981; 117: 425–430
   PubMedGoogle Scholar
• Krisans S. K., Mortensen R. M., Lazarow P. B. “Acyl CoA synthetase in rat liver peroxisomes: Computer-assisted analysis of cell fractionation experiments”. J. Biol. Chem 1980; 255: 9599–9607
   PubMed Web of Science ®Google Scholar
• Shindo Y., Hashimoto T. “Acyl coenzyme A synthetase and fatty acid oxidation in rat liver peroxisomes”. J. Biochem 1978; 84: 1177–1181
   PubMed Web of Science ®Google Scholar
• Mannaerts G. P., Van Veldhoven P., Van Broekhoven A., Vandebroek G., Debeer L. J. “Evidence that peroxisomal acyl CoA synthetase is located at the cytoplasmic side of the peroxisomal membrane”. Biochem. J. 1982; 204: 17–23
   PubMed Web of Science ®Google Scholar
• Dommes V., Baumgart C., Kunau W. H. Degradation of unsaturated fatty acids in peroxisomes: Existence of a 2,4-dienoyl CoA reductase pathway. J. Biol. Chem 1981; 256: 8259–8262
   PubMed Web of Science ®Google Scholar
• Hayashi H., Hino S., Yamasaki F. “Intraparticulate localization of some peroxisomal enzymes related to fatty acid β-oxidation”. Eur. J. Biochem 1981; 120: 47–51
   PubMedGoogle Scholar
• Panchenko L. F., Antonenkov V. D. “Glucose 6 phosphate dehydrogenase of rat liver peroxisomes”. Experientia 1984; 40: 467–468
   PubMedGoogle Scholar
• Gee R., McGroarty E., Hsieh B., Wied D. M., Tolbert N. E. “Glycerol phosphate dehydrogenase in mammalian peroxisomes”. Arch. Biochem. Biophys 1974; 161: 187–193
   Web of Science ®Google Scholar
• Leighton F., Brandan E., Lazo O., Bronfman M. “Subcellular fractionation studies on the organization of fatty acid oxidation by liver peroxisomes”. Ann. NY Acad. Sci. 1982; 386: 62–80
   PubMed Web of Science ®Google Scholar
• Lazarow P. B. Compartmentation of β-oxidation of fatty acids in peroxisomes. Metabolic Compartmentation, H. Sies. Academic Press, New York 1982; 317–329
   Google Scholar
• Bremer J., Osmundsen H. Fatty Acid Metabolism and Its Regulation. Elsevier Press. 1984, chap. 5.
   Google Scholar
• Hashimoto T. Individual peroxisome β-oxidation enzymes. Ann. NY Acad. Sci. 1982; 386: 5–12
   PubMed Web of Science ®Google Scholar
• Mortensen P. B., Klvraa S., Gregersen N., Rasmussen K. “Cyanide-insensitive and clofibrate enhanced β-oxidation of dodecanedioic acid in rat liver”. Biochem. Biophys. Acta 1982; 713: 393–397
   PubMed Web of Science ®Google Scholar
• Mizugaki M., Nishjmaki T., Yamamota H., Sagi M., Yamanaka H. Studies on the metabolism of unsaturated fatty acids. XI. Alterations in the activities of enoyl CoA hydratase, 3-hydroxacyl CoA epimerase and 2,4 dienoyl CoA reductase, in rat liver mitochondria and peroxisomes by clofibrate. J. Biochem 1982; 92: 2051–2054
   PubMed Web of Science ®Google Scholar
• Vamecq J., Van Hoof F. “Implication of a peroxisomal enzyme in the catabolism of glutaryl-CoA”. Biochem. J. 1984; 221: 203–211
   PubMed Web of Science ®Google Scholar
• Gray T. J. B., Beamand J. A., Lake B. G., Foster J. R., Gangolli S. D. “Peroxisome proliferation in cultured rat hepatocytes produced by clofibrate and phthalate ester metabolites”. Toxicol. Lett 1982; 10: 273–279
   PubMed Web of Science ®Google Scholar
• Gray T. J. B., Lake B. G., Beamand J. A., Foster J. R., Gangolli S. D. “Peroxisome proliferation in primary cultures of rat hepatocytes”. Toxicol. Appl. Pharmacol 1983; 67: 15–25
   PubMed Web of Science ®Google Scholar
• Furukawa K., Mochizuki Y., Sawada N. “Properties of peroxisomes and their induction by clofibrate in normal adult rat hepatocytes in primary culture”. In vitro 1984; 20: 573–584
   PubMedGoogle Scholar
• Reddy J. K., Bunyaratvej S., Svoboda D. Microbodies in experimentally altered cells. IV. Acatalasemic (CSb) mice treated with clofibrate. J. Cell Biol 1969; 42: 587–596
   PubMed Web of Science ®Google Scholar
• Lazarow P. B. “Three hypolipidemic drugs increase hepatic palmitoyl-CoA oxidation in the rat”. Science 1977; 197: 580–581
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Kumar N. S. “The peroxisome proliferation associated polypeptide in rat liver”. Biochem. Biophys. Res. Com-mun. 1977; 77: 824–829
   PubMed Web of Science ®Google Scholar
• Reddy M. K., Hollenberg P. F., Reddy J. K. Partial purification and immunoreactivity of an 80,000 molecular weight polypeptide associated with peroxisome proliferation in rat liver. Biochem. J. 1980; 188: 731–740
   PubMed Web of Science ®Google Scholar
• Reddy M. K., Qureshi S. A., Hollenberg P. F., Reddy J. K. Immunochemical identity of peroxisomal enoyl-CoA hydratase with the peroxisome-proliferation associated 80,000 molecular weight polypeptide in rat liver. J. Cell. Biol 1981; 89: 406–417
   PubMed Web of Science ®Google Scholar
• Antonenkov V. D., Pirozhkov S. V., Panchenko L. F. Effect of clofibrate on the polypeptide composition of a purified fraction of rat liver peroxisomes. Biochem. (USSR) 1983; 48: 1222–1229
   Web of Science ®Google Scholar
• Barnard S. D., Molello J. A., Caldwell W. J., LeBeau J. E. Comparative ultrastructural study of rat hepatocytes after treatment with the hypolipidemic agents probucol, clofibrate and fenofibrate. J. Toxicol. Environ. Health 1980; 6: 547–557
   PubMed Web of Science ®Google Scholar
• Holloway B. R., Thorp J. M. Induction of hepatic a-glycerophosphate dehydrogenase and peroxisomal enzymes by hypolipidaemic agents. Toxicol. Appl. Pharmacol 1979; 48(A125)250
   Google Scholar
• Stegmeier K., Schmidt F. H., Reinicke A., Fahimi H. D. “Triglyceride lowering effect and induction of liver enzymes in male rats after administration of hypolipidaemic drugs”. Ann. NY Acad. Sci. 1982; 386: 449–452
   Web of Science ®Google Scholar
• Reddy J. K., Azarnoff D. L., Svoboda D. J., Prasad J. D. “Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice: Absence of sex difference in response”. J. Cell. Biol 1974; 61: 344–358
   PubMed Web of Science ®Google Scholar
• Moody D. E., Reddy J. K. The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid and Wy-14,643) on hepatic peroxisome and peroxisome associated enzymes. Am. J. Pathol 1978; 90: 435–446
   PubMed Web of Science ®Google Scholar
• Ishii H., Suga T. Clofibrate-like effects of acetylsalicylic acid on peroxisomes and on hepatic and serum triglyeride levels. Biochem. Pharmacol 1979; 28: 2829–2833
   PubMed Web of Science ®Google Scholar
• Berge R. K., Hosy L. H., Aarsland A., Bakke O. M., Farstad M. “Enzymatic changes in rat liver associated with low and high doses of a peroxisome proliferator”. Toxicol. Appl. Pharamacol 1984; 73: 35–41
   PubMed Web of Science ®Google Scholar
• Osumi T., Hashimoto T. “Subcellular distribution of the enzymes of the fatty acyl CoA β-oxidation system and their induction by di(-2-ethylhexyl)phthlate in rat liver”. J. Biochem 1979; 85: 131–139
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Chiga M., Svoboda D. “Stimulation of liver catalase synthesis in rats by ethyl-a-p-chlorophenoxyisobutyrate”. Biochem. Biophys. Res. Commun 1971; 43: 318–324
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Kumar N. S. “Stimulation of catalase synthesis and increase of carnitine acetyltransferase activity in the liver of intact female rats fed clofibrate”. J. Biochem 1979; 85: 847–856
   PubMed Web of Science ®Google Scholar
• Van Veldhoven P., Declercq P. E., Debeer L. J., Man-Naerts G. P. “Effects of benofluorex and fenofibrate treatment on mitochondrial and peroxisomal marker enzymes in rat liver”. Biochem. Pharmacol 1984; 33: 1153–1155
   PubMed Web of Science ®Google Scholar
• Berge R. K., Flatmar T., Osmundsen H. “Enhancement of long chain acyl CoA hydrolase activity in peroxisomes and mitochondria of rat liver by peroxisome proliferators”. Eur. J. Biochem 1984; 141: 637–644
   PubMedGoogle Scholar
• Krahling J. B., Tolbert N. E. “Induction of hepatic peroxisomal and mitochondrial enzymes by high fat diets”. Ann. NY Acad. ScL 1982; 386: 433–435
   Web of Science ®Google Scholar
• Osmundsen H. “Peroxisomal β-oxidation of long fatty acids: Effects of high fat diets”. Ann. NY Acad. Sci 1982; 386: 13–29
   PubMed Web of Science ®Google Scholar
• Westerfeld W. W., Richert D. A., Ruegamer W. R. The role of the thyroid hormone in the efect of p-chloro-phenoxyisobutyrate in rats. Biochem. Pharmacol 1968; 17: 1003–1016
   PubMed Web of Science ®Google Scholar
• Kurup C. K. R., Aithal H. M., Ramasarma T. Increase in hepatic mitochondria on administration of ethyl-a-p-chlorophenoxyisobutyrate to the rat. Biochem. J. 1970; 116: 111–119
   PubMedGoogle Scholar
• Gear A. R. L., Albert A. D., Bednarek J. M. “The effect of the hypocholesterolemic drug clofibrate on liver mitochondrial biogenesis: A role for neutral mitochondrial proteases”. J. Biol. Chem 1974; 249: 6495–6504
   PubMed Web of Science ®Google Scholar
• Cederbaum A. I., Madhavan T. V., Rubin E. “Effect of chronic clofibrate administration on mitochondrial fatty acid oxidation”. Biochem. Pharmacol 1976; 25: 1285–1292
   PubMed Web of Science ®Google Scholar
• Mackerer C. R., Haettinger J. R. “Further studies concerning the effects of clofibrate on respiration and oxidative phosphorylation of rat liver mitochondria”. Biochem. Pharmacol 1974; 23: 3331–3345
   PubMed Web of Science ®Google Scholar
• Mittal B., Kurup C. K. “Purification of clofibrate-induced carnitine acetyltransferase from rat liver mitochondria”. Biochem. Biophys. Acta 1980; 619: 90–97
   PubMed Web of Science ®Google Scholar
• Solberg H. E., Aas M., Daae L. N. W. “The activity of the different carnitine acyltransferases in the liver of clofibrate fed rats”. Biochem. Biophys. Acta 1972; 280: 434–439
   PubMed Web of Science ®Google Scholar
• Mittal B., Kurup C. K. R. “Induction of carnitine acetyltransferase by clofibrate in rat liver”. Biochem. J. 1981; 194: 249–255
   PubMed Web of Science ®Google Scholar
• Christiansen R. Z., Osmundsen H., Borrebaek B., Bremer J. “The effects of clofibrate feeding on the metabolism of palmitate and erucate in isolated hepatocytes”. Lipids 1978; 13: 487–491
   PubMed Web of Science ®Google Scholar
• Voltti H., Hassinen I. E. “Effect of clofibrate on the hepatic concentrations of citric acid cycle intermediates and malonyl-CoA in the rat”. Life Sci 1981; 28: 47–51
   PubMed Web of Science ®Google Scholar
• Lipsky N. G., Pedersen P. L. Perturbation by clofibrate of mitochondrial levels in animal cells. J. Biol. Chem 1982; 257: 1473–1481
   PubMed Web of Science ®Google Scholar
• Lund H., Bremer J. Carnitine acetyltransferase: Effect of malonyl-CoA, fasting and clofibrate feeding in mitochondria from different tissues. Biochem. Biophys. Acta 1983; 750: 164–170
   PubMed Web of Science ®Google Scholar
• Holloway B. R., Orton T. C. The effect of hypolipidaemic agents on hepatic peroxisomal and microsomal drug metabolising enzymes in relation to thyroxine modulation. Br. J. Pharmacol 1980; 69: 318P
   Web of Science ®Google Scholar
• Kähönen M. T., Ylikahri R. H. “Effect of clofibrate and gemfibrozil on the activities of mitochondrial carnitine acyltransferases in rat liver”. Atherosclerosis 1979; 32: 47–56
   PubMed Web of Science ®Google Scholar
• Halvorsen O. “Effects of hypolipidemic drugs on hepatic CoA”. Biochem. Pharmacol 1983; 32: 1126–1128
   PubMed Web of Science ®Google Scholar
• Glatz J. F. C., Wagenmakers A. J. M., Veerkamp J. H., Van Moerkerk H. T. B. “Effect of clofibrate feeding on palmitate and branched-chain 2-oxo acid oxidation in rat liver and muscle”. Biochem. Pharmacol 1983; 32: 2489–2493
   PubMed Web of Science ®Google Scholar
• Shindo Y., Osumi T., Hashimoto T. “Effects of administration of di-(2-ethylhexyl)phthlate on rat liver mitochondria”. Biochem. Pharmacol 1978; 27: 2683–2688
   PubMed Web of Science ®Google Scholar
• Melnick R. L., Schiller C. M. “Mitochondrial toxicity of phthalate esters”. Environ. Health Perspect 1982; 45: 51–56
   PubMed Web of Science ®Google Scholar
• Bjorkhem L. “On the quantitative importance of u-oxidation of fatty acids”. J. Lipid Res. 1978; 19: 585–590
   PubMed Web of Science ®Google Scholar
• Bjorkhem I. “On the mechanism of regulation of w-oxidation of fatty acids”. J. Biol. Chem 1976; 251: 5259–5266
   PubMed Web of Science ®Google Scholar
• Wada F., Usami M., Goto M., Hayashi T. Studies on the physiological significance of fatty acid co-oxidation. J. Biochem 1971; 70: 1065–1067
   PubMed Web of Science ®Google Scholar
• Ruegamer W. R., Ryan N. T., Richert D. A., Westerfeld W. W. “The effects of p-chlorophenoxyisobutyrate on the turnover rate and distribution of thyroid hormone in the rat”. Biochem. Pharmacol 1969; 18: 613–624
   PubMed Web of Science ®Google Scholar
• Lee Y. P., Takemori A. E., Lardy H. “Enhanced oxidation of a-glycerophosphate by mitochondria of thyroid fed rats”. J. Biol. Chem 1959; 234: 3051–3054
   PubMed Web of Science ®Google Scholar
• Just W. W., Hartl F. Y. Rat liver peroxisomes. II. Stimulation of peroxisomal fatty acid β-oxidation by thyroid hormones. Hoppe-Seyler's Z. Physiol. Chem 1983; 364: 1541–1547
   PubMedGoogle Scholar
• Svoboda D., Azarnoff D., Reddy J. “Microbodies in experimentally altered cells. II. The relationship of microbody proliferation to endocrine glands”. J. Cell Biol 1969; 40: 734–746
   PubMed Web of Science ®Google Scholar
• Vessby B., Lithell H., Ledermann H. Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hyper-triglyceridaemic patients with bezafibrate. Atherosclerosis 1982; 44: 113–118
   PubMed Web of Science ®Google Scholar
• Mannaerts G. P., Debeer L. D., Thomas J., De Schep-Per P. J. “Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate treated rats”. J. Biol. Chem 1979; 254: 4585–4595
   PubMed Web of Science ®Google Scholar
• Moody D. E., Reddy J. K. “Serum triglyceride and cholesterol contents in male rats receiving diets containing plasticisers and analogues of the ester 2-ethylhexanol”. Toxicol. Lett 1982; 10: 379–383
   PubMed Web of Science ®Google Scholar
• Moody D. E., Reddy J. K., Azarnoff D. L. “Peroxisome-associated enzymes and serum lipids in tumour-bearing rats treated with peroxisome-proliferating agents”. Biochem. Pharmacol 1984; 33: 2591–2597
   PubMed Web of Science ®Google Scholar
• Ide T., Sugano M. “Effect of clofibrate on the metabolism of oleate in the perfused rat liver”. Biochem. Pharmacol 1983; 32: 2583–2588
   PubMed Web of Science ®Google Scholar
• Ghis M. P., Verrando D., Negrel R., Ailhaud G. “Utilization of glucose and palmitate during adipose conversion of OB 17 cells: Modulation by hypolipidaemic drugs”. J. Pharmacol 1984; 15: 17–25
   PubMedGoogle Scholar
• Chatterjee B., Demyan W. F., Lalwani N. D., Reddy J. K., Roy A. K. Reversible alteration of hepatic messenger RNA species for peroxisomal and non-peroxisomal proteins induced by the hypolipidaemic drug Wy-14,643. Biochem. J. 1983; 214: 879–883
   PubMed Web of Science ®Google Scholar
• Lazarow P. B., Robbi M., Fujiki Y., Wong L. Biogenesis of peroxisomal proteins in vivo and in vitro. Ann. NY Acad. Sci. 1982; 386: 285–300
   PubMed Web of Science ®Google Scholar
• Fujiki Y., Fowler S., Shio H., Hubbard A. L., Lazarow P. B. Polypeptide and phospholipid composition of the membrane of rat liver peroxisomes: Comparison with endoplasmic reticulum and mitochondrial membranes. J. Cell Biol 1982; 93: 103–110
   PubMed Web of Science ®Google Scholar
• Conney A. H. “Pharmacological implications of microsomal enzyme induction”. Pharmacol. Rev. 1967; 19: 317–366
   PubMed Web of Science ®Google Scholar
• Facino M. R., Carini M., Bertuletti R., Tofanetti O. ““In vitro” metabolism of bezafibrate in rat liver”. Pharmacol. Res. Commun 1981; 13: 121–131
   PubMedGoogle Scholar
• Albro P. W., Chae K., Philpot R., Corbett J. T., Schroeder J., Jordan S. In vitro metabolism of MEHP by microsomal enzymes. Drug Metab. Dispos 1984; 12: 742–748
   PubMed Web of Science ®Google Scholar
• Neat C. E., Thomassen S., Osmundsen H. “Induction of peroxisomal O-oxidation in rat liver by high-fat diets”. Biochem. J. 1980; 186: 369–371
   PubMed Web of Science ®Google Scholar
• Nilsson A., Thomassen M. S., Christiansen E. Long chain acyl CoA levels in liver from rats fed high fat diets: Is it of significance for an increased peroxisomal β-oxidation?. Lipids 1984; 19: 187–194
   PubMed Web of Science ®Google Scholar
• Berge R. K., Hosøy L. H., Farstad M. N. Influence of dietary status on liver palmitoyl CoA hydrolase, peroxisomal enzymes, CoASH and long chain acyl CoA in rats. Int. J. Biochem 1984; 16: 403–410
   PubMedGoogle Scholar
• Jakobsson S., Thor H., Orrenius S. “Fatty acid inducible cytochrome P-454 of rat kidney cortex microsomes”. Biochem. Biophys. Res. Commun 1970; 39: 1073–1080
   PubMed Web of Science ®Google Scholar
• Narbonne J. F., Pelissier M. A., Bonnamour D., Borin C., Albrecht R. “Lipid composition and mono-oxygenase relationship in liver microsomal membranes from rats fed unbalanced diets”. Toxicol. Lett 1984; 23: 73–77
   PubMed Web of Science ®Google Scholar
• Lalwani N. D., Fahl W. E., Reddy J. K. “Detection of a nafenopin-binding protein in rat liver cytosol associated with the induction of peroxisome proliferation by hypolipidaemic compounds”. Biochem. Biophys. Res. Commun 1983; 116: 388–393
   PubMed Web of Science ®Google Scholar
• Fahl W. E., Lalwani N. D., Reddy M. K., Reddy J. K. Induction of peroxisomal enzymes in livers of neonatal rats exposed to lactating mothers treated with hypolipidaemic drugs. Biochem. J. 1983; 210: 875–883
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Eisen H. J., Negishi M., Lang M. A., Hjelmeland L. M., Okey A. B. “Genetic mechanisms controlling the induction of polysubstrate monooxygenase (P-450) activities”. Ann. Rev. Pharmacol. Toxicol 1981; 21: 431–462
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Bausserman L. L. “Aryl hydrocarbon hydroxylase induction in cell culture as a function of gene expression”. Ann. NY Acad. Sci. 1971; 179: 561–579
   PubMed Web of Science ®Google Scholar
• Poland A., Glover E., Kende A. Stereospecific, high affinity binding of 2,3,7,8-tetrachorodibenzo-p-dioxin by hepatic cytosol: Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol. Chem 1976; 251: 4936–4946
   PubMed Web of Science ®Google Scholar
• Okey A. B., Bondy G. P., Mason M. E., Kahl G. F., Eisen H. J., Guenthner T. M., Nebert D. W. “Regulatory gene product of the Ah locus: Characterization of the cytosolic inducer-receptor complex and evidence for its nuclear translocation”. J. Biol. Chem 1979; 254: 11636–11648
   PubMed Web of Science ®Google Scholar
• Small G. M., Burdett K., Connock N. V. Clofibrate-induced changes in enzyme activities in liver, kidneys and small intestine of male mice. Ann. NY Acad. Sci. 1982; 386: 460–463
   Web of Science ®Google Scholar
• Le Hir M., Dubach U. C. Peroxisomal and mitochondrial β-oxidation in the rat kidney: Distribution of fatty acyl-coenzyme A oxidase and 3-hydroxy acyl CoA dehydrogenase activities along the nephron. J. Histochem. Cytochem 1982; 30: 441–444
   PubMed Web of Science ®Google Scholar
• Sasame H. A., Thorgeirsson S. S., Mitchell J. R., Gillette J. R. The possible involvement of cytochrome b5 in the oxidation of lauric acid by microsomes from kidney cortex and liver of rats. Life Sci 1974; 14: 35–46
   PubMed Web of Science ®Google Scholar
• Ellin A., Orrenius S., Pilotti A., Swahn C. G. “Cytochrome P-450k of rat kidney cortex microsomes: Further studies on its interaction with fatty acids”. Arch. Biochem. Biophys 1973; 158: 597–604
   PubMed Web of Science ®Google Scholar
• Okita R. T., Parkhill L. K., Yasokochi Y., Masters B. S. S., Theoharides A. D., Kupfer D. The ω- and (ω-1) hydroxylase activities of prostaglandin A1 and E1 and lauric acid by pig kidney microsomes and a purified kidney cytochrome P-450. J. Biol. Chem 1981; 256: 5961–5964
   PubMed Web of Science ®Google Scholar
• Morrison A. R., Pascoe N. “Metabolism of arachidonate through NADPH-dependent oxygenation of renal cortex”. Proc. Natl. Acad. Sci. 1981; 78: 7375–7378
   PubMed Web of Science ®Google Scholar
• Svoboda D., Grady H., Azarnoff D. “Microbodies in experimentally altered cells”. J. Cell Biol 1967; 35: 127–152
   PubMed Web of Science ®Google Scholar
• Reddy M. K., Lalwani N. D., Qureshi S. A., Reddy J. K. Induction of hamster hepatic peroxisomal β-oxidation and peroxisome proliferation-associated 80,000 molecular weight polypeptide by hypolipidaemic drugs. Human Toxicol 1982; 1: 135–147
   PubMedGoogle Scholar
• Grey R. H., DeLa Iglesia F. A. “Quantitative microscopy comparison of peroxisome proliferation by the lipid-regulating agent gemfibrozil in several species”. Hepatology 1984; 4: 520–530
   PubMed Web of Science ®Google Scholar
• Lake B. G., Gray T. J. B., Foster J. R., Stubberfield C. R., Gangolli S. D. “Comparative studies on DEHP induced hepatic peroxisome proliferation in rat and hamster”. Toxicol. Appl. Pharmacol 1984; 72: 46–60
   PubMed Web of Science ®Google Scholar
• Bell F. P. Effects of phthalate esters on lipid metabolism in various tissues, cells and organelles in mammals. Environ. Health Perspect 1982; 45: 41–50
   PubMed Web of Science ®Google Scholar
• Jackh R., Rhodes C., Grasso P., Carter J. T. “Genotoxicity studies on di(2-ethyhexyl) phthalate and adipate and toxicity studies on di(2-ethylhexyl) phthalate in the rat and marmoset”. FoodChem. Toxicol 1984; 22: 151–155
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Lalwani N. D., Qureshi S. A., Reddy M. K., Moehle C. M. “Induction of hepatic peroxisome proliferation in non-rodent species including primates”. Am. J. Pathol 1984; 114: 171–183
   PubMed Web of Science ®Google Scholar
• Olsson A. G., Oro L. “Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia”. Atherosclerosis 1982; 42: 229–243
   PubMed Web of Science ®Google Scholar
• Hanefeld M., Kemmer C., Leonhardt W., Kunze K. D., Jaross W., Haller H. Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver. Atherosclerosis 1980; 36: 159–172
   PubMed Web of Science ®Google Scholar
• Hanefeld M., Kemmer C., Kadner E. “Relationship between morphological changes and lipid lowering action of /j-chloro-phenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man”. Atherosclerosis 1983; 46: 239–246
   PubMed Web of Science ®Google Scholar
• Bliimcke S., Schwartzkopff W., Lobeck H., Edmondson N. A., Prentice D. E., Blane G. F. “Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients”. Atherosclerosis 1983; 46: 105–116
   PubMed Web of Science ®Google Scholar
• Gariot P., Pointel J. P., Barrat E., Drouin D., Debry G. “Etude morphometrique des peroxysomes hepatiques chez des malades hyperlipoproteinemiques traites par fenofibrate”. Biomed. Pharmacother 1984; 38: 101–106
   PubMedGoogle Scholar
• De la Iglesia F. A., Pinn S. M., Lucas J., McGuire E. J. “Quantitative sterology of peroxisomes in hepatocytes from hyperlipoproteinemic patients receiving gemfibrozil”. Micron 1981; 12: 97–98
   Web of Science ®Google Scholar
• De la Iglesia F. A., Lewis J. E., Buchanan R. A., Marcus E. L., McMahon G. “Light and electron microscopy of liver in hyperlipoproteinemic patients under long term gemfibrozil treatment”. Atherosclerosis 1982; 43: 19–37
   PubMed Web of Science ®Google Scholar
• Purchase I. F. H. “Range of experimental evidence in assessing potential human carcinogenicity”. Arch. Toxicol., Suppl 1980; 3: 283–293
   PubMedGoogle Scholar
• Bridges B. A. “An approach to the assessment of risk to man from DNA damaging agents”. Arch. Toxicol., Suppl 1980; 3: 271–281
   PubMedGoogle Scholar
• Warren J. R., Simmon V. F., Reddy J. K. Properties of hypolipidaemic peroxisome proliferators in the lymphocyte 3H thymidine and Salmonella mutagenesis assay. Cancer Res 1980; 40: 36–41
   PubMed Web of Science ®Google Scholar
• Fitzgerald J. E., Sanyer J. L., Schardein J. L., Lake R. S., Mc Guire E. J., De la Iglesia F. A. “Carcinogen bioassay and mutagenicity studies with the hypolipidaemic agent gemfibrozil”. J. Natl. Cancer Inst 1981; 67: 1105–1116
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Lalwani N. D., Reddy M. K., Qureshi S. A. “Excessive accumulation of auto-fluorescent lipofuscin in the liver during hepatocarcinogenesis by methyl clofenapate and other hypolipidaemic peroxisome proliferators”. Cancer Res 1982; 42: 259–266
   PubMed Web of Science ®Google Scholar
• Glauert H. P., Reddy J. K., Kennan W. S., Sattler G. L., Rao V. S., Pitot H. C. “Effect of hypolipidemic peroxisome proliferators on unscheduled DNA synthesis in cultured hepatocytes and on mutagenesis in Salmonella”. Cancer Lett 1984; 24: 147–156
   PubMed Web of Science ®Google Scholar
• Linnainmaa K. Induction of sister chromatid exchange by the peroxisome proliferators 2,4-D, MCPA and clofibrate in vivo and in vitro. Carcinogenesis 1984; 5: 703–707
   PubMed Web of Science ®Google Scholar
• Ruddick J. A., Villeneuve D. C., Chu I., Nestman E., Miles D. “An assessment of the teratogenicity in the rat and mutagenicity in Salmonella of mono-2-ethylhexylphthalate”. Bull. Environ. Contam. Toxicol 1981; 27: 181–186
   PubMed Web of Science ®Google Scholar
• Kornbrust D. J., Barfknecht T. R., Ingram D., Shelburne J. D. Effect of di(2-ethylhexyl)phthalate on DNA repair and lipid peroxidation in rat hepatocytes and on metabolic cooperation in Chinese hamster V-79 cells. J. Toxiol. Environ. Health 1984; 75: 99–116
   Google Scholar
• Svoboda D. J., Azarnoff D. L. Tumours in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res 1979; 39: 3419–3428
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Qureshi S. A. “Tumorigenicity of the hypolipidemic peroxisome proliferator ethyl-a-p-chloro-phenoxyisobutyrate (clofibrate) in rats”. Br. J. Cancer 1979; 40: 476–482
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Rao M. S., Moody D. E. Hepatocellular carcinomas in acatalasemic mice treated with nafenopin a hypolipidemic peroxisome proliferator. Cancer Res 1976; 36: 1211–1217
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Rao M. S. Malignant tumours in rats fed nafenopin, a hepatic peroxisome proliferator. J. Natl. Cancer Inst 1977; 59: 1645–1650
   PubMed Web of Science ®Google Scholar
• Lalwani N. D., Reddy M. K., Qureshi S. A., Reddy J. K. Development of hepatocellular carcinomas and increased peroxisomal fatty acid β-oxidation in rats fed 4 chloro-6-(2,3-xylidino)-2-pyrimidinylthio acetic acid (Wy-14,643) in the semipurified diet. Carcinogenesis 1981; 2: 645–650
   PubMed Web of Science ®Google Scholar
• Hartig F., Stegmeier K., Heboid G., Ozel M., Fahimi H. D. “Study of liver enzymes: Peroxisome proliferation and tumour rates in rats at the end of carcinogenicity studies with bezafibrate and clofibrate”. Ann. NY Acad. Sci. 1982; 386: 464–467
   Web of Science ®Google Scholar
• Rao M. S., Lalwani N. D., Watanabe T. K., Reddy J. K. Inhibitory effect of antioxidants ethoxyquin and 2(3)-ter/-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed cipro-fibrate, a peroxisome proliferator. Cancer Res 1984; 44: 1072–1076
   PubMed Web of Science ®Google Scholar
• Kluwe W. M., Haseman J. K., Douglas J. F., Huff J. E. “The carcinogenicity of dietary di-(2-ethylhexyl)phthalate (DEHP) in Fischer 344 rats and B6C3F mice”. J. Toxicol. Environ. Health 1982; 10: 797–815
   PubMed Web of Science ®Google Scholar
• Northup S., Martis L., Ulbricht R., Garber J., Miripol J., Schmitz T. “Comment on the carcinogenic potential of di-(2-ethyl-hexyl)phthalate”. J. Toxicol. Environ. Health 1982; 10: 493–518
   PubMed Web of Science ®Google Scholar
• Kluwe W. M., Haseman J. K., Huff J. E. “The carcinogenicity of di-(2-ethylhexyl)phthalate (DEHP) in perspective”. J. Toxicol. Environ 1983; 12: 159–169
   Web of Science ®Google Scholar
• Rao M. S., Lalwani N. D., Reddy J. K. Sequential histologic study of rat liver during peroxisome proliferator 4-chloro-6-(2,3-xylidino)2-pyrimidinylthiolacetic acid (Wy-14,643) induced carcinogenesis. J. Natl. Cancer Inst 1984; 73: 983–990
   PubMed Web of Science ®Google Scholar
• Rao M. S., Lalwani N. D., Scarpelli D. G., Reddy J. K. The absence of 7-glutamyl-transpeptidase activity in putative preneoplastic lesions and in hepatocellular carcinomas induced in rats by the hypolipidemic peroxisome proliferator Wy-14,643. Carcinogenesis 1982; 3: 1231–1233
   PubMed Web of Science ®Google Scholar
• Berenblum I. Contemporary studies of carcinogenesis (biological aspects). Carcinogenesis as a Biological Problem, A. Neuberger, E. L. Tatum. North Holland Publishing Company, Oxford 1974; vol. 34: 67–167
   Google Scholar
• Taussig M. J. Neoplasia. Processes in Pathology. Blackwell Scientific Publications. 1984; 689–809
   Google Scholar
• Williams G. M. “Liver carcinogenesis: The role for some chemicals of an epigenetic mechanism of liver tumour promotion involving modification of the cell membrane”. Food Cosmet. Toxicol 1981; 19: 577–583
   PubMedGoogle Scholar
• Reddy J. K., Rao M. S. Enhancement of Wy-14,643, a hepatic peroxisome proliferator, of diethylnitrosamine-initiated hepatic tumorigenesis in the rat. Br. J. Cancer 1978; 38: 537–543
   PubMed Web of Science ®Google Scholar
• Mochizuki Y., Furukawa K., Sawada N. “Effects of various concentrations of ethyl-a-p-chlorophenoxyisobutyrate (clofibrate) on diethylnitrosamine-induced hepatic tumorigenesis in the rat”. Carcinogenesis 1982; 3: 1027–1029
   PubMed Web of Science ®Google Scholar
• Schulte-Hermann R., Timmermann-Trosiener I., Schuppler J. “Promotion of spontaneous preneoplastic cells in rat liver as a possible explanation of tumour production by non-mutagenic compounds”. Cancer Res 1983; 43: 839–844
   PubMed Web of Science ®Google Scholar
• Stäubli W., Bentley P., Bieri F., Frohlich E., Waechter F. “Inhibitory effect of nafenopin upon the development of DEN-induced enzyme altered foci within rat liver”. Carcinogenesis 1984; 5: 41–46
   PubMed Web of Science ®Google Scholar
• Perera M. I. R., Shinozuka H. Accelerated regression of carcinogen induced preneoplastic hepatocycte foci by peroxisome proliferators, BR-931, 4-chloro-6(2,3-xylidino)-2-pyrimidinyl-thio (N-β-hydroxyethyl) acetamide and di-(2-ethylhexyl)phthal-ate. Carcinogenesis 1984; 5: 1193–1198
   PubMed Web of Science ®Google Scholar
• Stott W. T., Reitz R. H., Schumann A. M., Watanabe P. G. “Genetic and nongenetic events in neoplasia”. Food Cosmet. Toxicol 1981; 19: 567–576
   PubMedGoogle Scholar
• Goldenberg H., Hiittinger M., Kampfer P., Kramar R., Pavelka M. Effect of clofibrate application on morphology and enzyme content of liver peroxisomes. Histochemisty 1976; 46: 189–196
   PubMedGoogle Scholar
• Von Daniken A., Lutz W. K., Schlatter C. “Lack of covalent binding to rat liver DNA of the hypolipidaemic drugs clofibrate and fenofibrate”. Toxicol. Lett 1981; 7: 306–310
   Web of Science ®Google Scholar
• Von Däniken A., Lutz W. K., Jäckh R., Schlatter C. Investigation of the potential for binding of DEHP and DEHA to liver DNA in vivo. Toxicol. Appl. Pharmacol 1984; 73: 373–387
   PubMed Web of Science ®Google Scholar
• Fahl W. E., Lalwani N. D., Watanabe T., Goel S., Reddy J. K. “DNA damage related to increased hydrogen peroxide generation by hypolipidaemic drug-induced liver peroxisomes”. Proc. Natl. Acad. Sci. 1984; 81: 7827–7830
   PubMed Web of Science ®Google Scholar
• Stogniew M., Fenselau C. “Electrophilic reactions of acyl-linked glucuronides: Formation of clofibrate mercapturate in humans”. Drug Metab. Dispos 1982; 10: 609–613
   PubMed Web of Science ®Google Scholar
• Ciriolo M. R., Rossi L., Mavelli I., Rotilid G., Borzatta V., Cristofori M., Bartanti M. The effects of hypolipidemic agents derived from procetofenic acid on the activity of superoxide dismutase and glutathione peroxidase and on malonyl dialdehyde production of rat liver. Arzneim. Forsch 1984; 34: 465–467
   PubMed Web of Science ®Google Scholar
• Kawashima Y., Katoh H., Kozuka H. “Sex-related difference in the effect of clofibric acid on induction of two novel long chain acyl Co A hydrolases in rat liver”. Biochim. Biophys. Acta 1982; 712: 48–56
   PubMed Web of Science ®Google Scholar
• Kawashima Y., Katoh H., Nakajima S., Kozuka H. “Induction of hepatic long-chain acyl-CoA hydrolase by clofibric acid administration”. Biochim. Biophys. Acta 1983; 752: 182–185
   PubMed Web of Science ®Google Scholar
• Katoh H., Nakajima S., Kawashima Y., Kozuka H., Uchiyama M. “Induction of rat hepatic long chain acyl-CoA hydrolases by various peroxisome proliferators”. Biochem. Pharmacol 1984; 33: 1081–1085
   PubMed Web of Science ®Google Scholar
• Kawashima Y., Hirose A., Kozuka H. “Selective increase in acylation of 1-acylglycerophosphorylcholine in livers of rats and mice by peroxisome proliferators”. Biochim. Biophys. Acta 1984; 793: 232–237
   PubMed Web of Science ®Google Scholar
• Awasthi Y. C., Singh S. V., Goel S. K., Reddy J. K. Irreversible inhibition of hepatic glutathione-S-transferase by ciprofibrate, a peroxisome proliferator. Biochem. Biophys. Res. Commun 1984; 123: 1012–1018
   PubMed Web of Science ®Google Scholar
• Foliot A., Touchard D., Celier C. “Impairment of hepatic glutathione-S-transferase activity as a cause of reduced biliary sulfobromophthalien excretion in clofibrate-treated rats”. Biochem. Pharmacol 1984; 33: 2829–2834
   PubMed Web of Science ®Google Scholar